Back
Globus Medical 10K Form
Buy
59
GMED
Globus Medical
Last Price:
$83.44
Seasonality Move:
2.91%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
2024-05-07 | 10Q | GMED/Globus Medical Quarterly |
2023-11-07 | 10Q | GMED/Globus Medical Quarterly |
2023-08-03 | 10Q | GMED/Globus Medical Quarterly |
2023-05-04 | 10Q | GMED/Globus Medical Quarterly |
2022-11-08 | 10Q | GMED/Globus Medical Quarterly |
2022-08-04 | 10Q | GMED/Globus Medical Quarterly |
Receive GMED News And Ratings
See the #1 stock for the next 7 days that we like better than GMED
GMED Financial Statistics
Sales & Book Value
Annual Sales: | $1.6B |
---|---|
Cash Flow: | $161.7M |
Price / Cash Flow: | 38.96 |
Annual Sales: | $29.94 |
Price / Book: | 2.79 |
Profitability
EPS (TTM): | 0.67000 |
---|---|
Net Income (TTM): | $91.5M |
Gross Margin: | $1B |
Return on Equity: | 2.27% |
Return on Assets: | 1.8% |
Globus Medical Earnings Forecast
Key Globus Medical Financial Ratios
-
The Gross Profit Margin over the past 15 years for GMED is 65.05%.
-
The Selling, General & Administrative Expenses for GMED have been equal to 41.02% of Gross Profit Margin.
-
The Research & Development expenses have been 7.91% of Revenue.
-
The Interest Expense is -11.22% of Operating Income.
-
The Net Earning history of GMED is 7.83% of Total Revenues.
-
Per Share Earnings over the last 15 years have been positive in 8 years.
Globus Medical Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | NYSE |
---|---|
Industry: | Health Care Equipment & Supplies |
Sector: | Health Care |
Current Symbol: | GMED |
CUSIP: | 379577 |
Website: | globusmedical.com |
Debt
Debt-to-Equity Ratio: | 0.11 |
---|---|
Current Ratio: | 2.51 |
Quick Ratio: | 1.57 |
Price-to-Earnings
Trailing P/E Ratio: | 78.01 |
---|---|
Forward P/E Ratio: | 24.41 |
GMED Technical Analysis vs Fundamental Analysis
Buy
59
Globus Medical (GMED)
is a Buy
Is Globus Medical a Buy or a Sell?
-
Globus Medical stock is rated a BuyThe current Globus Medical [GMED] share price is $83.47. The Score for GMED is 59, which is 18% above its historic median score of 50, and infers lower risk than normal.